Promising phase II results in chronic kidney disease
Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
Search
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
Ethical Business Practices
Suppliers shall conduct their business in an ethical manner and act with integrity.
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
sustainably fighting rabies info hub
Did you know that every nine minutes, rabies takes a human life? Find out how we support the elimination of this deadly disease.
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
empa-reg-outcome-recurrent-events
EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease
New positive data in Phase III type 2 diabetes trial
DINAMO Phase III trial demonstrated empagliflozin significantly reduced blood sugar levels in children and adolescents with type 2 diabetes
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Joint venture to fight Antimicrobial Resistance
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
European_Commission_approves_nintedanibSSc-ILD
Nintedanib is approved as the first and only treatment of systemic sclerosis-associated interstitial lung disease
FDA accepts new chronic kidney disease treatment application
FDA accepts new chronic kidney disease treatment application
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
EASi-HF™ Phase III trial in patients with HFpEF
Boehringer Ingelheim's Sandy Sommer on the global urgency for innovative heart failure care and the significance of the clinical trial for patients with HFpEF worldwide.
EASi-KIDNEY™ Phase III trial for people with CKD
Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
New treatment for chronic kidney disease approved in the EU
The European Commission (EC) has approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Performance Indicators
Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH
Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction